Hatzivassiliou G, Zhao F, Bauer DE, et al: ATP citrate lyase inhibition can suppress tumor cell growth. In: Cancer Cell. 8. Jahrgang, Nr.4, Oktober 2005, S.311–21, doi:10.1016/j.ccr.2005.09.008, PMID 16226706.
Migita T, Narita T, Nomura K, et al: ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. In: Cancer Res. 68. Jahrgang, Nr.20, Oktober 2008, S.8547–54, doi:10.1158/0008-5472.CAN-08-1235, PMID 18922930.
Ray KK, Bays HE, Catapano AL, et al: Safety and efficacy of bempedoic acid to reduce LEL cholesterol. In: N. Engl. J. Med. 380. Jahrgang, Nr.11, März 2019, S.1022–1032, doi:10.1056/NEJMoa1803917.
elsevier.com
linkinghub.elsevier.com
Tosukhowong P, Borvonpadungkitti S, Prasongwatana V, et al: Urinary citrate excretion in patients with renal stone: roles of leucocyte ATP citrate lyase activity and potassium salts therapy. In: Clin. Chim. Acta. 325. Jahrgang, Nr.1–2, November 2002, S.71–8, PMID 12367768 (elsevier.com).
nih.gov
ncbi.nlm.nih.gov
Tosukhowong P, Borvonpadungkitti S, Prasongwatana V, et al: Urinary citrate excretion in patients with renal stone: roles of leucocyte ATP citrate lyase activity and potassium salts therapy. In: Clin. Chim. Acta. 325. Jahrgang, Nr.1–2, November 2002, S.71–8, PMID 12367768 (elsevier.com).
Hatzivassiliou G, Zhao F, Bauer DE, et al: ATP citrate lyase inhibition can suppress tumor cell growth. In: Cancer Cell. 8. Jahrgang, Nr.4, Oktober 2005, S.311–21, doi:10.1016/j.ccr.2005.09.008, PMID 16226706.
Migita T, Narita T, Nomura K, et al: ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. In: Cancer Res. 68. Jahrgang, Nr.20, Oktober 2008, S.8547–54, doi:10.1158/0008-5472.CAN-08-1235, PMID 18922930.